X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Panacea Biotech with Lupin Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs LUPIN LTD - Comparison Results

PANACEA BIOTECH    Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

LUPIN LTD 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH LUPIN LTD PANACEA BIOTECH/
LUPIN LTD
 
P/E (TTM) x -21.1 28.3 - View Chart
P/BV x 2.5 3.0 84.5% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 PANACEA BIOTECH   LUPIN LTD
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-14
LUPIN LTD
Mar-18
PANACEA BIOTECH/
LUPIN LTD
5-Yr Chart
Click to enlarge
High Rs1491,465 10.2%   
Low Rs82727 11.3%   
Sales per share (Unadj.) Rs84.1349.6 24.1%  
Earnings per share (Unadj.) Rs-18.35.6 -329.4%  
Cash flow per share (Unadj.) Rs-6.729.6 -22.6%  
Dividends per share (Unadj.) Rs05.00 0.0%  
Dividend yield (eoy) %00.5 0.0%  
Book value per share (Unadj.) Rs83.7300.3 27.9%  
Shares outstanding (eoy) m61.25452.08 13.5%   
Bonus/Rights/Conversions -ESOPS-  
Price / Sales ratio x1.43.1 43.8%   
Avg P/E ratio x-6.3197.2 -3.2%  
P/CF ratio (eoy) x-17.237.1 -46.5%  
Price / Book Value ratio x1.43.6 37.8%  
Dividend payout %090.0 0.0%   
Avg Mkt Cap Rs m7,074495,502 1.4%   
No. of employees `0002.817.0 16.1%   
Total wages/salary Rs m1,44928,647 5.1%   
Avg. sales/employee Rs Th1,874.19,273.6 20.2%   
Avg. wages/employee Rs Th527.01,681.0 31.3%   
Avg. net profit/employee Rs Th-407.7147.4 -276.6%   
INCOME DATA
Net Sales Rs m5,154158,042 3.3%  
Other income Rs m1001,504 6.6%   
Total revenues Rs m5,254159,545 3.3%   
Gross profit Rs m-76631,475 -2.4%  
Depreciation Rs m71110,859 6.5%   
Interest Rs m1,5032,044 73.6%   
Profit before tax Rs m-2,88120,076 -14.3%   
Minority Interest Rs m11-71 -15.2%   
Prior Period Items Rs m-635 -16.2%   
Extraordinary Inc (Exp) Rs m1,771-14,644 -12.1%   
Tax Rs m172,885 0.6%   
Profit after tax Rs m-1,1212,513 -44.6%  
Gross profit margin %-14.919.9 -74.7%  
Effective tax rate %-0.614.4 -4.1%   
Net profit margin %-21.81.6 -1,368.5%  
BALANCE SHEET DATA
Current assets Rs m3,810122,095 3.1%   
Current liabilities Rs m8,36550,956 16.4%   
Net working cap to sales %-88.445.0 -196.4%  
Current ratio x0.52.4 19.0%  
Inventory Days Days15685 184.0%  
Debtors Days Days67120 56.1%  
Net fixed assets Rs m14,480129,876 11.1%   
Share capital Rs m61904 6.8%   
"Free" reserves Rs m903134,866 0.7%   
Net worth Rs m5,127135,771 3.8%   
Long term debt Rs m5,83264,245 9.1%   
Total assets Rs m19,433263,054 7.4%  
Interest coverage x-0.910.8 -8.5%   
Debt to equity ratio x1.10.5 240.4%  
Sales to assets ratio x0.30.6 44.1%   
Return on assets %2.01.7 113.4%  
Return on equity %-21.91.9 -1,181.7%  
Return on capital %3.63.7 97.7%  
Exports to sales %24.50-   
Imports to sales %10.20-   
Exports (fob) Rs m1,264NA-   
Imports (cif) Rs m525NA-   
Fx inflow Rs m1,53953,141 2.9%   
Fx outflow Rs m94219,335 4.9%   
Net fx Rs m59733,807 1.8%   
CASH FLOW
From Operations Rs m59917,512 3.4%  
From Investments Rs m-438-14,073 3.1%  
From Financial Activity Rs m-303-14,921 2.0%  
Net Cashflow Rs m-141-11,482 1.2%  

Share Holding

Indian Promoters % 74.5 46.6 159.9%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 0.6 11.3 5.3%  
FIIs % 1.3 31.9 4.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 10.1 233.7%  
Shareholders   10,259 98,259 10.4%  
Pledged promoter(s) holding % 35.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   STERLING BIOTECH  PFIZER  ALEMBIC PHARMA  ORCHID PHARMA LTD  SANOFI INDIA  

Compare PANACEA BIOTECH With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

LUPIN LTD 2017-18 Annual Report Analysis (Annual Result Update)

Aug 16, 2018 | Updated on Aug 16, 2018

Here's an analysis of the annual report of LUPIN LTD for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of LUPIN LTD. Also includes updates on the valuation of LUPIN LTD.

LUPIN LTD Announces Quarterly Results (1QFY19); Net Profit Up 21.3% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, LUPIN LTD has posted a net profit of Rs 4 bn (up 21.3% YoY). Sales on the other hand came in at Rs 26 bn (up 3.2% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Lupin: US Markets Drags down Revenues and Net Profits (Quarterly Results Update - Detailed)

Nov 2, 2017

Domestic markets registers robust growth in the quarter

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Sep 21, 2018 (Close)

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH - UNICHEM LAB COMPARISON

COMPARE PANACEA BIOTECH WITH

MARKET STATS